Deal of the Day — limited-time pharmacy picks!
Erlotero 150mg tablet

Erlotero 150mg tablet

Salt Composition: Erlotinib

Expiry Date: 01/2028

Special offer

Buy at $79.49

$79.49

Inclusive of all taxes

▼

30 Tablets in Strip

About The Product

Non-small cell lung cancer


Description

Erlotero 150mg tablet is a Target therapy based anticancer medication prescribed by the doctor to treat advanced Non Small Cell Lung Cancer (NSCLC) with specific EGFR gene mutation as well as Pancreatic Cancer in combination with other medicine.

Erlotero 150mg tablet contains Erlotinib that blocks cancer cell growth and proliferation via angiogenesis.

Common Side Effects

  • Erlotero 150mg tablet is a chemical based anti cancer medication.
  • Like any other chemotherapeutic drug, it also has multiple side effects that range from common to extreme.
  • Consult your doctor, if symptoms persists for longer period of time or if you experience any of the serious side effects. ● Vomiting ● Nausea ● Fatigue ● Diarrhea ● Decreased Appetite ● Abdominal Pain ● Dry Skin ● Mouth Sores ● Constipation ● Rashes ● Weight Loss ● Headache ● Arthralgia ● Dyspnea ● Pneumonitis ● Vision Related Issues

Dosage And Administration

  • The standard recommended starting dosage of Erlotero 150mg tablet is once daily.
  • This medicine is taken orally as whole on an empty stomach, without breaking, biting or chewing.
  • Consult your doctor for exact dosage that is especially meant for you.

Mechanism Of Action

Erlotero 150mg tablet contains Erlotinib that belongs to the class of tyrosine kinase inhibitor. Erlitinib blocks the abnormal EGFR protein kinase that is responsible for cancer cell growth and proliferation via angiogenesis.

Abnormal EGFR protein blockage inhibits cancer cell growth.

Faqs

Erlotero 150mg tablet cause harm to growing fetus as well as is teratogenic in nature.

Thus, it is not recommended during pregnancy for treatment.

References

• Becker, A., van Wijk, A., Smit, E. F., & Postmus, P.

E. (2010).

Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 5(9), 1477-1480. • Tang, P.

A., Tsao, M. S., & Moore, M.

J. (2006).

A review of erlotinib and its clinical use. Expert opinion on pharmacotherapy, 7(2), 177-193. • Abdelgalil, A.

A., Al-Kahtani, H. M., & Al-Jenoobi, F.

I. (2020).

Erlotinib. In Profiles of drug substances, excipients and related methodology (Vol.

45, pp. 93-117).

Academic Press. • Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., & Ciardiello, F.

(2007). Erlotinib in non-small cell lung cancer treatment: current status and future development.

The oncologist, 12(7), 840-849.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026